Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population

International Clinical Psychopharmacology

Volumn 22, Issue 1, 2007, Pages 1-11

  Duncan, Erica ^a,b   Dunlop, Boadie W ^b   Boshoven, William ^a,b   Woolson, Sandra L ^c   Hamer, Robert M ^c,d   Phillips, Lawrence S ^b  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d IL   (United States)

Author keywords

Adverse events; Antipsychotic agents; Diabetes mellitus; Glucose; Hyperglycemia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; RISPERIDONE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; DRUG EXPOSURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; SIDE EFFECT; UNITED STATES;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; CHLORPROMAZINE; COHORT STUDIES; FEMALE; FLUPHENAZINE; HALOPERIDOL; HOSPITALS, VETERANS; HUMANS; HYPERGLYCEMIA; INCIDENCE; MALE; MIDDLE AGED; PERPHENAZINE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; RISPERIDONE; SOUTHEASTERN UNITED STATES; TIME FACTORS; VETERANS;

EID: 33845644676     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000224792.44276.20     Document Type: Article

References (45)

1. Allison DB, Mentore JL, Moonseong H, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696.
2. American Diabetes Association (1999). Screening for type 2 diabetes. Diabetes Care 22:20S-23S.
3. American Diabetes Association (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601.
4. American Diabetes Association (2005). Standards of medical care in diabetes. Diabetes Care 28:S4-S36.
5. Baptista T, Kin NM, Beaulieu S, de Baptista EA (2002). Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35:205-219.
6. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins DS, Breier A, Jovanovic L (2003). A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 56:164-170.
7. Caro JJ, Ward A, Levinton C, Robinson K (2002). The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 63:1135-1139.
8. Center for Disease Control (2005). National diabetes fact sheet. Available at: http://www.cdc.gov/diabetes/pubs/figuretext.htm#fig1 [Accessed 27 June 2006].
9. Dixon L,Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, Lehman A (2000). Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 26:903-912.
10. Dunlop BW, Sternberg M, Phillips LS, Andersen J, Duncan E (2003). Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics. Psychopharmacol Bull 37:99-117.
11. Dwyer DS, Donohoe D (2003). Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 75:255-260.
12. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003). Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26:S5-S20.
13. Feldman PD, Hay LK, Deberdt W, Kennedy JS, Hutchins DS, Hay DP, et al. (2004). Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. J Am Med Dir Assoc 2004:38-46.
14. Fuller MA, Shermock KM, Secic M, Grogg AL (2003). Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 23:1037-1043.
15. Gianfrancesco F, Grogg A, Mahmound R, Markowitz J, Nasrallah H (2001). Differential effects of antipsychotics on type II diabetes: findings from a large health plan database. In Annual meeting of the Society of Biological Psychiatry. New Orleans, Los Angeles.
16. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang R-h, Nasrallah HA (2002). Differential effects of risperidone, olanzapine, clozapine and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 63:920-930.
17. Gianfrancesco FD, White R, Wang R-h, Nasrallah HA (2003). Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 23:328-335.
18. Harris MI (1993). Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 16:642-652.
19. Hedenmalm K, Hagg S, Stahl M, Mortimer O, Spigset O (2002). Glucose intolerance with atypical antipsychotics. Drug Safety 25:1107-1116.
20. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC (2000). Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157:975-981.
21. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. (2005). Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62:19-28.
22. Koller E, Doraiswamy PM (2002). Olanzapine-associated diabetes mellitus. Pharmacotherapy 22:841-852.
23. Koller E, Schneider B, Bennett K, Dubitsky G (2001). Clozapine-associated diabetes. Am J Med 111:716-723.
24. Koller EA, Cross JT, Doraiswamy PM, Schneider B (2003). Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 23:735-744.
25. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, et al. (2002). Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br Med J 325:243-247.
26. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. (2003). H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526.
27. Leslie DL, Rosenheck RA (2004). Incidence of newly diagnosed diabetes attributable to atypical antipsychotic. Am J Psychiatry 161:1709-1711.
28. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223.
29. Lund BC, Perry PJ, Brooks JM, Arndt S (2001). Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia and hypertension. Arch Gen Psychiatry 58:1172-1176.
30. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. (2004). Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161:1334-1349.
31. McIntyre RS, McCann SM, Kennedy SH (2001). Antipsychotic metabolic effects: weight gain, diabetes mellitus and lipid abnormalities. Can J Psychiatry 46:273-281.
32. Melkersson K, Dahl ML (2004). Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 64:701-723.
33. Mukherjee S (1995). High prevalence of type II diabetes in schizophrenic patients. Schizophr Res 15:195.
34. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL (1996). Diabetes mellitus in schizophrenic patients. Compr Psychiatry 37:68-73.
35. Newcomer JW (2004). Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 18:36-46.
36. Newcomer JW (2005). Second-generation (atypical). antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19:1-93.
37. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G (2002). Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59:337-345.
38. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R (2002). Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159:561-566.
39. Silvestre JS, Prous J (2005). Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Meth Find Exp Clin Pharmacol 27:289-304.
40. Subramaniam M, Chong SA, Pek E (2003). Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 48:345-347.
41. Sumiyoshi T, Roy A, Jayathilake K, Meltzer HY (2004). The effect of hypertension and obesity on the development of diabetes mellitus in patients treated with atypical antipsychotic drugs. J Clin Psychopharmacol 24:452-454.
42. Tabata H, Kikuoka M, Kikuoka H, Bessho H, Hirayama J, Hanabusa T, et al. (1987). Characteristics of diabetes mellitus in schizophrenic patients. J Med Assoc Thai 70:90-93.
43. United States Census Data (2004). US interim projections by age, sex, race, and Hispanic origin. Available at: http://www.census.gov/ipc/www/ usinterimproj/ [Accessed 27 June 2006].
44. Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J (2002). Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol 22:236-243.
45. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC (2002). The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63:856-865.